Non-profit partnership seeks sustainability for the pharmaceutical industry.
For a Sustainable Pharma Supply Chain: Schreiner MediPharm Among Founding Members of “Alliance to Zero”
The Alliance to Zero pursues the goal of launching net-zero pharmaceutical products in regulated markets by 2030 at latest. To achieve this, the founding members have committed to developing a joint net-zero offering by 2026 to provide pharmaceutical companies with enough time to finalize their overall product on this basis.
The Alliance has developed a roadmap for a net-zero emissions concept for pharmaceutical production and the supply chain. Currently necessary steps and a harmonized language are being developed, and principles are being defined for evaluating and monitoring the entire emissions footprint of pharmaceutical end products. In addition, the Alliance is planning to collaborate with academic and non-profit organizations pursuing similar goals.
Dr. Thomas Schweizer, President of Schreiner MediPharm emphasizes the importance of the company’s membership in the Alliance: “For Schreiner MediPharm, as a pioneer in the production of innovative functional labels, sustainability starts as early as in product development that considers all lifecycles to achieve a reduced environmental footprint. For us, co-founding the Alliance to Zero means another important step toward holistic sustainability. We are convinced that, together with the other alliance partners, we will be able to drive the development of net-zero pharmaceutical products.”
In addition to Schreiner MediPharm, the founding members of the Alliance represent other renowned companies of the pharmaceutical and biotech value chain: Dätwyler, Harro Höfliger, HealthBeacon, Körber Pharma, SCHOTT, Sharp, and Ypsomed. Thus, the Alliance encompasses component suppliers, machine manufacturers and assembly/manufacturing service providers, manufacturers of primary and secondary packaging, and companies responsible for final product assembly or handle products that have been returned after use.
The founding members of the Alliance to Zero regard their collaboration along the pharmaceutical supply chain as an important step in driving fundamental change to reduce climate footprint. The close collaboration across traditional company boundaries, as well as the specialized expertise and individual know-how of each cooperation partner, results in the development of holistic solutions that will have a positive impact on the pharmaceutical industry.
# # #
Caption: The Alliance to Zero is an important step on the road to net-zero emissions in the pharmaceutical supply chain.
# # #
About Schreiner MediPharm
Based in the Munich area of Germany, Schreiner MediPharm is a global leader in the development and manufacture of innovative specialty labels with value-added benefits that have set the standard in the healthcare and pharmaceutical industries. Schreiner MediPharm’s expertise is based on 70 years of experience. The family-owned company provides specialty labels and label printing services to the biggest names in the healthcare market around the world.
About Alliance to Zero
The Alliance to Zero is a Swiss-based, non-profit membership association that aims to facilitate the transition of the pharmaceutical sector to compliance with Net Zero emissions in line with the goals of the Paris Climate Agreement. The alliance was founded in June 2021 by eight pharmaceutical supply organisations whose collaboration represents the complete value chain of pharma products. Further information can be found at: www.alliancetozero.com.
For further information, contact:
Schreiner MediPharm, a business unit of
Schreiner Group LP
300 Corporate Drive, Suite 10
Blauvelt, NY 10913
Phone (845) 848-9000
Fax (845) 848-9041